Regulus Therapeutics
RGLS
#7200
Rank
โ‚น52.34 B
Marketcap
โ‚น756.11
Share price
0.00%
Change (1 day)
460.86%
Change (1 year)

Regulus Therapeutics (RGLS) - Total liabilities

Total liabilities on the balance sheet as of March 2025 : โ‚น0.53 Billion

According to Regulus Therapeutics's latest financial reports the company's total liabilities are โ‚น0.53 Billion. A companyโ€™s total liabilities is the sum of all current and non-current debts and obligations.

Regulus Therapeutics - Total liabilities on balance sheet (from 2011 to 2025)

Total liabilities by year

Year Total liabilities Change
2024-12-31โ‚น0.66 B-16.24%
2023-12-31โ‚น0.79 B-28.34%
2022-12-31โ‚น1.11 B10.59%
2021-12-31โ‚น1.00 B18.63%
2020-12-31โ‚น0.84 B-46.19%
2019-12-31โ‚น1.57 B-33.38%
2018-12-31โ‚น2.36 B-13.15%
2017-12-31โ‚น2.71 B-10.24%
2016-12-31โ‚น3.02 B168.11%
2015-12-31โ‚น1.13 B-54.82%
2014-12-31โ‚น2.50 B36.74%
2013-12-31โ‚น1.82 B-19.35%
2012-12-31โ‚น2.26 B-49.18%
2011-12-31โ‚น4.46 B

Total liabilities for similar companies or competitors

Company Total liabilities differencediff. Country
Sanofi
SNY
โ‚น6.291 T 1,171,014.18%๐Ÿ‡ซ๐Ÿ‡ท France
Biogen
BIIB
โ‚น1.226 T 228,230.46%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
โ‚น6.056 T 1,127,323.25%๐Ÿ‡บ๐Ÿ‡ธ USA
AstraZeneca
AZN
โ‚น6.065 T 1,128,961.75%๐Ÿ‡ฌ๐Ÿ‡ง UK
GSK plc
GSK
โ‚น6.555 T 1,220,115.59%๐Ÿ‡ฌ๐Ÿ‡ง UK
Sangamo Therapeutics
SGMO
โ‚น7.31 B 1,261.16%๐Ÿ‡บ๐Ÿ‡ธ USA
Alnylam Pharmaceuticals
ALNY
โ‚น406.85 B 75,629.91%๐Ÿ‡บ๐Ÿ‡ธ USA